

Appl. No. 10/028,952  
Amdt. dated January 16, 2004  
Reply to Office Action of October 16, 2003

**Amendments to the Specification**

Please replace the following paragraphs in the specification as shown below:

**Page 2, first full paragraph:**

A novel, specific, mammary cell growth inhibitor, Mammastatin, has recently been identified and characterized. Mammastatin has been expressed from variant clones, Mamma (PCT/US97/18026, ATCC# 97451, deposited 22 February 1996); MammB (PCT/US97/27147, ATCC# PTA-2091, deposited 15 June 2000); and MammC, described in copending PCT application No. PCT/US00/16933, filed on even date herewith (ATCC# PTA-2090, deposited 15 June 2000).

**Page 3, second full paragraph:**

The ECGI of the invention are expressed in normal epithelial cells but not in cancerous epithelial cells. The Mammastatin-like ECGI proteins are encoded by nucleic acid sequences that hybridize to nucleic acid sequences encoding Mammastatin. The ECGI proteins also bind anti-Mammastatin antibody. A nucleic acid sequence encoding ECGI in prostate cells (PRT-6, SEQ ID NO: 4) has been isolated and characterized (PRT-6, ATCC# PTA-2092, deposited 15 June 2000), as described in the Examples below.

**Page 7, first paragraph:**

Mammastatin-like epithelial cell growth inhibitors preferably have substantial identity (at least 90%, and preferably at least 95% identity) over approximately 1000 contiguous nucleotides of a nucleic acid sequence encoding Mammastatin. Nucleic acids encoding Mammastatin include those DNA inserts of Mamma (PCT/US97/18026, ATCC# 97451, deposited 22 February 1996); MammB (PCT/US97/27147, ATCC# PTA-2091, deposited 15 June 2000); and MammC, described herein (ATCC# PTA-2092, deposited 15 June 2000). Consensus sequences determined for known Mammastatin clones are shown in the Comparative Sequence Table 5 below, and as SEQ ID NO: 1 (Mamma); SEQ ID NO: 2 (MammB); SEQ ID NO: 3 (MammC). Prostate ECGI nucleic acid sequence (SEQ ID NO: 4) is shown in Tables 1, 2, and 5.

Appl. No. 10/028,952  
Amdt. dated January 16, 2004  
Reply to Office Action of October 16, 2003

**Amendments to the Specification**

Please replace the following paragraphs in the specification as shown below:

**Page 4, please replace paragraphs 1 and 2 with the following:**

Figure 1 shows hybridization of a nucleic acid sequence encoding Mammastatin to RNA of specific tissues. Figure 1A is a schematic diagram of an mRNA test panel showing locations of specific tissue mRNAs for analysis; Figure 1B is a computer scanned image of a Northern blot showing hybridization of Mammastatin nucleic acid sequence to mRNA from a variety of tissues according to the plan shown in Figure 1A.

**Page 19, first full paragraph:**

The prostate ECGI sequence (SEQ ID NO: 4) was analyzed against nucleic acid sequences present in GenBank. Portions of two molecules showed some similarity to domains within the prostate ECGI sequence: 28SmRNA (SEQ ID NO: 7) and Hip55 (SEQ ID NO: 8).

**Page 5, please insert the following paragraph after paragraph 2:**

**Biological Deposits:**

Biological materials, including hybridomas and plasmids recited in the specification having ATCC Accession Numbers, were deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110, under the provisions of the Budapest Treaty.

Appl. No. 10/028,952  
Amndt. dated January 16, 2004  
Reply to Office Action of October 16, 2003

### Amendments to the Specification

Please replace the following paragraphs in the specification as shown below:

#### Page 32:

```
1851 AGACAGCTTG GCTCTTGCCC CTGACAGGAT ACTGAGCCAA GCCCTGCCTG
TCTGTGGAAC CGAGAACGGG GACTGTCCTA TGA CTGCGTT CGGGACGGAC
W P S P E W P L P S C G E G S *
1901 TGGCCAAGCC CTGAGTGGCC ACTGCCAAGC TGGCGGGAAG GGTCTGAGC
ACCGGTTTCGG GACTCACC GG TGACGGTTTCG ACGCCCTTC CCAGGACTCG
G A S G R L W L P S A F I C L
1951 AGGGGCATCT GGGAGGCTCT GGCTGCCTTC TGCATTTATT TGCCTTTTTT
TCCCGTAGA CCCTCCGAGA CCGACGGAAG ACGTAAATAA ACGGAAAAAA
F S L A S K G W W P P L P R M
2001 CTTTTCTCT TGCTTCTAAG GGGTGGTGGC CACCACTGTT TAGAATGACC
GAAAAAGAGA ACGAAGATT CCACACCG GTGGTGACAA ATCTTACTGG
L G N S E R R E L F L A E F V T
2051 CTTGGGAACA GTGAACGTAG AGAATTGTTT TTAGCAGAGT TTGTGACCAA
GAACCTTGT CACTTGATC TCTTAACAAA AATCGTCTCA AACACTGGTT
V R V D H G G L A A G N L S C
2101 AGTCAGAGTG GATCATGGTG GTTTGGCAGC AGGGAATTTG TCTTGTGGA
TCAGTCTCAC CTAGTACCAC CAAACCGTCG TCCCTTAAAC AGAACAACCT
L L C A P H S I S L S L C L G
2151 GCCTGCTCTG TGCTCCCCAC TCCATTTCTC TGTCCCTCTG CCTGGGCTAT
CGGACGAGAC ACGAGGGGTG AGGTAAAGAG ACAGGGAGAC GGACCCGATA
G K W G C R W P S S H P G Y S K
2201 GGGAAAGTGGG GATGCAGATG GCCAAGCTCC CACCCTGGGT ATTCAAAAAC
CCCTTCACCC CTACGTCTAC CGGTTTCGAGG GTGGGACCCA TAAGTTTTTG
A D T T C S S T R L T R C L Q
2251 GGCAGACACA ACATGTTTCT CCACGCGGCT CACTCGATGC CTGCAGGCCC
CCGTCTGTGT TGTACAAGGA GGTGCGCCGA GTGAGCTACG GACGTCCGGG
V C A S T D S D F R K S K K K
2301 CAGTGTGTGC CTCAACTGAT TCTGACTTCA GGAAAGTAA AAAAAAAAAA
GTCACACACG GAGTTGACTA AGACTGAAGT CCTTTTCATT TTTTTTTTTT
K K L E K L W T S S [SEQ ID NO: 9]
2351 AAAAAACTCG AGAAGCTTG GACTTCTTCG CCA [SEQ ID NO: 41]
TTTTTTGAGC TCTTCGAAC CTGAAGAAGC GGT
```

Appl. No. 10/028,952  
Amdt. dated January 16, 2004  
Reply to Office Action of October 16, 2003

### Amendments to the Specification

Please replace the following paragraphs in the specification as shown below:

#### Page 35:

```
1851 ATCACACTCC AGATCTCTCC ATACCACACT GCTAGCACAT GTGCCTGTCA
TAGTGTGAGG TCTAGAGAGG TATGGTGTGA CGATCGTGTA CACGGACAGT
. L I P G S C Y F P F Y F L S L
1901 TCTTATTCCT GGCTCCTGTT ATTTCCTTTT TTATTCCTTT TCCCTTCCTC
AGAATAAGGA CCGAGGACAA TAAAGGGAAA AATAAAGGAA AGGGAAGGAG
. T T P F S P H F F S F F L I V
1951 CCACAACCCC TTTTTCGCCC CATTTCCTTT CTTTCTTTT AATTGTTAAT
GGTGTGAGGG AAAAAGGGGG GTAAAGAAAA GAAAGAAAA TTAACAATTA
Y I T N T C L S E Q L I * H K R
2001 TACATAACTA ATACATGCTT ATCAGAACAA TTGATATAGC ACAAAGGAT
ATGTATTGAT TATGTACGAA TAGTCTGTGTT AACTATATCG TGTTCCTTA
. * S T G E * * L I P V I L A L
2051 ATAAAGTACG GGTGAGTGAT AGCTCATCCC TGTAATCCTA GCACTTTGGA
TATTCATGTC CCACTCACTA TCGAGTAGGG ACATTAGGAT CGTGAAACCT
. A K A G R S L E S R V R D Q P
2101 AGGCCAAGGC AGGCAGATCA CTTGAGTCCA GAGTTCGAGA CCAGCCTGGG
TCCGGTTCGG TCCGTCTAGT GAACTCAGGT CTCAAGCTCT GGTCCGACCC
Q H G E T L S L Q K N T K I * P
2151 CAACATGGTG AAACCTGTG TCTACAAAAA AATACAAAAA TTTAGCCGGG
GTTGTACCAC TTGCGACAG AGATGTTTTT TTATGTTTTT AAATCGGCCC
. V L A H T C S L S Y S E G * G
2201 CGTGCTGGCA CACACCTGTA GTCTCAGCTA CTCTGAGGGC TGAGGTGGGA
GCACGACCGT GTGTGGACAT CAGAGTCGAT GAGACTCCCG ACTCCACCCT
. I D * A Q E V E A A A V R * D
2251 AGATTGATTG AGCCCAGGAG GTGGAAGCTG CAGCAGTGCG CTGAGATTGC
TCTAACTAAC TCGGGTCCTC CACCTTCGAC GTCGTCACGC GACTCTAACG
A I A L Q P G * E R E T L S Q K
2301 GCCATTGCAC TCCAGCCTGG GTGAGAGAGA GAGACCCTGT CTCAAAAAAA
CGGTAACGTG AGGTCGGACC CACTCTCTCT CTCTGGGACA GAGTTTTTTT
. K
2351 AAAAA [SEQ ID NO: 10]
TTTTT [SEQ ID NO: 3]
```